

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

VOLUNTARY ANNOUNCEMENT – UPDATE ON PROGRESS FOR RECOMBINANT HUMANIZED ANTI-IL-17A MONOCLONAL ANTIBODY INJECTION

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis. Reference is also made to the overseas regulatory announcement of the Company dated 24 June 2019.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that recently, the acceptance notice for new drug application from the National Medical Products Administration (the “**NMPA**”) with the acceptance number CXSL1900061 Guo (CXSL1900061國) was issued for the “recombinant humanized anti-IL-17A monoclonal antibody injection” (product code: JS005) independently developed by the Company with proprietary intellectual property rights. Below is the basic information of the new drug:

Product name: Recombinant humanized anti-IL-17A monoclonal antibody injection

Acceptance No.: CXSL1900061 Guo (CXSL1900061國)

Subject matter: New drug application: Special access programme

Applicants: Shanghai Junshi Biosciences Co., Ltd.*; Suzhou Junmeng Biosciences Co., Ltd. (蘇州君盟生物醫藥科技有限公司); Shanghai Junshi Biotechnology Co., Ltd.* (上海君實生物工程有限公司); and Suzhou Union Biopharm Biosciences Co., Ltd.* (蘇州眾合生物醫藥科技有限公司).

Conclusion: New Drug Application Accepted

The Company will, according to the progress of new drug application for the project, perform the information disclosure obligation in a timely manner. Investors are advised to pay continuous attention in this regard.

Cautionary Statement required by Rule 18A.05 of the Listing Rules of the Stock Exchange:
The Company may not be able to ultimately develop and market JS005 successfully. Investors are reminded to exercise caution.

By order of the Board of
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 24 June 2019

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Wu Hai and Dr. Yao Sheng as executive Directors; Mr. Tang Yi, Mr. Li Cong, Mr. Yi Qingqing and Mr. Lin Lijun as non-executive Directors; and Dr. Chen Lieping, Dr. He Jia, Mr. Chen Xinjun, Mr. Qian Zhi and Dr. Roy Steven Herbst as independent non-executive Directors.

* *For identification purpose only*